Cargando…
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
Autores principales: | Hunault-Berger, M, Maillard, N, Himberlin, C, Recher, C, Schmidt-Tanguy, A, Choufi, B, Bonmati, C, Carré, M, Couturier, M-A, Daguindau, E, Marolleau, J-P, Orsini-Piocelle, F, Delaunay, J, Tavernier, E, Lissandre, S, Ojeda-Uribe, M, Sanhes, L, Sutton, L, Banos, A, Fornecker, L M, Bernard, M, Bouscary, D, Saad, A, Puyade, M, Rouillé, V, Luquet, I, Béné, M C, Hamel, J-F, Dreyfus, F, Ifrah, N, Pigneux, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520397/ https://www.ncbi.nlm.nih.gov/pubmed/28574488 http://dx.doi.org/10.1038/bcj.2017.50 |
Ejemplares similares
-
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022) -
Filo-Bobos /
por: Cortés Hernández, Jaime
Publicado: (1994) -
Los filos
por: Martínez Gamba, Magaly, 1948-
Publicado: (1981) -
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
por: Michallet, Anne-Sophie, et al.
Publicado: (2023) -
P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
por: Schavgoulidze, A., et al.
Publicado: (2022)